Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development	$ 1,700	$ 621,927	$ 690,705	$ 3,135,413
General and administrative	593,739	1,187,035	4,505,256	4,475,642
Total operating expenses	595,439	1,808,962	5,195,961	7,611,055
Loss from operations	(595,439)	(1,808,962)	(5,195,961)	(7,611,055)
Other income (expense):
Interest expense, net	(606,824)	(445,363)	(1,999,164)	(1,400,249)
PPP loan forgiveness		253,347		253,347
Gain on derecognition of non-financial asset			16,951,477
Reimbursement for expenses - related party	237,165		484,657
Change in fair value of derivative on debt	105,662	145,449	37,740	239,278
Loss on debt conversion			(257,810)	(27,504)
Total other income (expense)	(263,997)	(46,567)	15,216,900	(935,128)
Net income (loss) before non-controlling interests	(859,436)	(1,855,529)	10,020,939	(8,546,183)
Net loss attributable to non-controlling interests	(81,501)	(293,001)	(363,465)	(949,295)
Net income (loss) attributable to Oncotelic Therapeutics, Inc.	$ (777,935)	$ (1,562,528)	$ 10,384,404	$ (7,596,888)
Basic net loss per share attributable to common stock	$ (0.00)	$ (0.00)	$ 0.03	$ (0.03)
Basic weighted average common stock outstanding	386,751,480	370,443,893	385,610,191	279,358,671
Diluted net loss per share attributable to common stock	$ (0.00)	$ (0.00)	$ 0.02	$ (0.03)
Diluted weighted average common stock outstanding	386,751,480	370,443,893	420,738,409	279,358,671